GA-INVERIS-TRAINING
2.2.2021 18:17:08 CET | Business Wire | Press release
InVeris Training Solutions, the leading provider of integrated live-fire and virtual weapons training products and services for armed forces and law enforcement, will display a broad range of innovative solutions on two stands during the biennial International Defence Exhibition and Conference at the Abu Dhabi National Exhibition Centre (ADNEC) in the UAE, Feb. 21-25, 2021. IDEX will be InVeris’ first major international trade show following its rebranding in October 2020 from Meggitt Training Systems.
“Thanks to new, dynamic ownership, InVeris Training Solutions is now better positioned than ever to deliver superior in-house military and law enforcement expertise, combined with local support across our portfolio,” said Andrea Czop, vice president of strategy, sales and marketing. “Our advanced virtual, live-fire and integrated solutions can help Middle Eastern and other military forces better prepare to act at a moment’s notice to counter emerging and evolving threats.”
The company will have a dual presence at IDEX again for 2021. At stand #02-A01, InVeris will showcase its extensive live-fire portfolio, including models of three key products: The GranTrap™ granulated rubber bullet trap, Shoot House Optimized for Tactical Training (SHOTT™) tactical environment for critical skills training, and Road Range™ self-contained, transportable weapons training facility. Targeting systems will also feature prominently, including the XWT , the industry’s first wireless, 360-degree turning target retrieval system, as well as the Multi-Function Stationary Infantry Target (MF-SIT) that can respond to hits or a pre-programmed scenario, ensuring trainees do not anticipate target actions. Finally, the LOMAH (location of miss and hit) system provides the information needed to accurately display shot grouping and zeroing of weapons more effectively, resulting in improved marksmanship skills. Combined with a variety of shooting lanes and control systems, no other company can provide a comparable total firing range solution.
On the International Golden Group stand (#04-C20), InVeris will display the FATS® 180MIL simulation training system that puts users in the action, facing realistic pressures while maintaining situational awareness. The system utilizes the same high-fidelity ballistic engine validated by the US Army, Marine Corps and other military customers. The FATS 180MIL at IDEX will be complemented by a selection of simulated weapons, including the wireless M249 BlueFire® , M24 Sniper Rifle (Remington 700), M4 BlueFire, Glock 17 BlueFire and AK-47. For more than three decades, FATS has been the leader in virtual training, serving as the system of record for NATO military forces and other allies, along with law enforcement departments around the world. The FATS 180MIL and 300MIL are InVeris’ latest offerings in this market.
To speak with an InVeris representative during IDEX 2021, visit one of the stands above or schedule an appointment at https://inveristraining.com/about-inveris-training-solutions/request-a-meeting-with-inveris/ .
About InVeris Training Solutions
InVeris Training Solutions combines an agile approach with an unmatched expertise in training technology to design and deliver customized, cutting-edge, first-rate training solutions that keep military, law enforcement, private and commercial range clients safe, prepared and ready to serve – Because Seconds Matter™. With a portfolio of technology-enabled training solutions, and a team of 400 employees driven to innovate, InVeris Training Solutions is the global leader in integrated live-fire and virtual weapons training solutions. With its legacy companies, FATS® and Caswell, InVeris Training Solutions has fielded over 15,000 live-fire ranges and 7,500 virtual systems globally during its 90-year history. The company is headquartered in Suwanee, Georgia and partners with clients in the US and around the world from facilities on five continents.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005940/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom